AWS
BMRN icon

Atria Wealth Solutions’s BioMarin Pharmaceuticals BMRN Stock Holding History

Atria Wealth Solutions’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-9,709
Closed -$686K – 1508
2025
Q1 		$686K Buy
+9,709
New +$653K 0.01% 1045
2024
Q3 		– Sell
-2,542
Closed -$209K – 1930
2024
Q2 		$209K Sell
2,542
-7,296
-74% -$607K ﹤0.01% 1747
2024
Q1 		$859K Buy
9,838
+109
+1% +$9.76K 0.01% 977
2023
Q4 		$938K Buy
9,729
+153
+2% +$13.5K 0.01% 889
2023
Q3 		$847K Buy
9,576
+461
+5% +$41K 0.01% 888
2023
Q2 		$790K Buy
9,115
+631
+7% +$59.4K 0.01% 949
2023
Q1 		$825K Buy
8,484
+1,566
+23% +$162K 0.01% 874
2022
Q4 		$716K Sell
6,918
-176
-2% -$16.5K 0.01% 914
2022
Q3 		$601K Sell
7,094
-3,224
-31% -$287K 0.01% 928
2022
Q2 		$855K Buy
10,318
+2,206
+27% +$176K 0.02% 757
2022
Q1 		$625K Buy
+8,112
New +$679K 0.01% 940

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Atria Wealth Solutions's BMRN Position: Q2 2025 in Review

Atria Wealth Solutions sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2025, closing a stake of 9,709 shares — an estimated $686K sold.

Atria Wealth Solutions first reported a position in BMRN in Q1 2022 and held it in 11 quarters. The position peaked at $938K in Q4 2023. 582 funds tracked by Wall St. Rank hold BMRN as of Q2 2025.

  • Atria Wealth Solutions reported no remaining BioMarin Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Atria Wealth Solutions sold 9,709 BioMarin Pharmaceuticals shares in Q2 2025, an estimated $686K.
  • Atria Wealth Solutions first reported a position in BioMarin Pharmaceuticals in Q1 2022 and held it in 11 quarters.
  • Atria Wealth Solutions's BioMarin Pharmaceuticals position peaked at $938K in Q4 2023.
  • 582 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2025.

Based on Atria Wealth Solutions's 13F filing for Q2 2025, filed 25 Jul 2025.